<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="case-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Infect Dis Rep</journal-id><journal-id journal-id-type="iso-abbrev">Infect Dis Rep</journal-id><journal-id journal-id-type="publisher-id">idr</journal-id><journal-title-group><journal-title>Infectious Disease Reports</journal-title></journal-title-group><issn pub-type="ppub">2036-7430</issn><issn pub-type="epub">2036-7449</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407649</article-id><article-id pub-id-type="pmc">PMC12101389</article-id>
<article-id pub-id-type="doi">10.3390/idr17030047</article-id><article-id pub-id-type="publisher-id">idr-17-00047</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Bone Marrow Infection by <italic toggle="yes">Pneumocystis jirovecii</italic> in a Patient with AIDS: A Case Report and Literature Review</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3935-4394</contrib-id><name><surname>Cubides-Diaz</surname><given-names>Diego Alejandro</given-names></name><xref rid="af1-idr-17-00047" ref-type="aff">1</xref><xref rid="c1-idr-17-00047" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0002-2979-1312</contrib-id><name><surname>Negrette-Lazaro</surname><given-names>Valentina</given-names></name><xref rid="af2-idr-17-00047" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Poveda-Hurtado</surname><given-names>Viviana</given-names></name><xref rid="af3-idr-17-00047" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>L&#x000f3;pez-Salazar</surname><given-names>Juan Pablo</given-names></name><xref rid="af4-idr-17-00047" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Calder&#x000f3;n-Vargas</surname><given-names>Carlos Mauricio</given-names></name><xref rid="af5-idr-17-00047" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>&#x000c1;lvarez-Moreno</surname><given-names>Carlos Arturo</given-names></name><xref rid="af6-idr-17-00047" ref-type="aff">6</xref><xref rid="af7-idr-17-00047" ref-type="aff">7</xref></contrib></contrib-group><aff id="af1-idr-17-00047"><label>1</label>Department of Internal Medicine, Universidad Nacional de Colombia, Bogot&#x000e1; 111321, Colombia</aff><aff id="af2-idr-17-00047"><label>2</label>Faculty of Medicine, Universidad del Rosario, Bogot&#x000e1; 111221, Colombia; <email>valentina.negrette@urosario.edu.co</email></aff><aff id="af3-idr-17-00047"><label>3</label>Department of Internal Medicine, Universidad de La Sabana, Ch&#x000ed;a 250001, Colombia; <email>vivianapohu@unisabana.edu.co</email></aff><aff id="af4-idr-17-00047"><label>4</label>Department of Internal Medicine, Hospital Universitario de La Samaritana, Zipaquir&#x000e1; 250252, Colombia; <email>juanplopez9504@gmail.com</email></aff><aff id="af5-idr-17-00047"><label>5</label>Department of Internal Medicine, Hospital Universitario de La Samaritana, Bogot&#x000e1; 110411, Colombia; <email>caldecal@gmail.com</email></aff><aff id="af6-idr-17-00047"><label>6</label>Faculty of Medicine, Universidad Nacional de Colombia, Bogot&#x000e1; 111321, Colombia; <email>calvarez@colsanitas.com</email></aff><aff id="af7-idr-17-00047"><label>7</label>Cl&#x000ed;nica Universitaria Colombia, Cl&#x000ed;nica Colsanitas S.A., Bogot&#x000e1; 111321, Colombia</aff><author-notes><corresp id="c1-idr-17-00047"><label>*</label>Correspondence: <email>dicubidesd@unal.edu.co</email>; Tel.: +57-3105586634</corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>17</volume><issue>3</issue><elocation-id>47</elocation-id><history><date date-type="received"><day>08</day><month>3</month><year>2025</year></date><date date-type="rev-recd"><day>21</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>27</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Background: <italic toggle="yes">Pneumocystis jirovecii</italic> primarily causes pneumonia in immunosuppressed individuals, particularly those living with advanced HIV/AIDS. Extrapulmonary dissemination is uncommon, with bone marrow involvement described in only a handful of cases globally. Bone marrow infection occurs in the setting of severe immunosuppression, poses diagnostic challenges, and carries a high mortality rate. Methods: We describe the case of a 34-year-old man newly diagnosed with HIV/AIDS, presenting with severe immunosuppression and <italic toggle="yes">Pneumocystis jirovecii</italic> pneumonia. The patient initially improved with cotrimoxazole and corticosteroids, but was readmitted shortly after discharge with abdominal pain, diarrhea, and worsening pancytopenia. A bone marrow biopsy revealed <italic toggle="yes">Pneumocystis jirovecii</italic> cysts, confirming disseminated infection. Concomitant Kaposi sarcoma involving the skin and gastrointestinal tract was also diagnosed. Despite antimicrobial therapy, the patient&#x02019;s condition worsened, leading to multisystem organ failure and death two months later. Conclusions: This case highlights a rare presentation of disseminated <italic toggle="yes">Pneumocystis jirovecii</italic> infection with bone marrow involvement in a patient with advanced HIV/AIDS. Although infrequent, this complication should be considered in individuals with <italic toggle="yes">Pneumocystis jirovecii</italic> pneumonia who develop persistent cytopenias and systemic symptoms. Diagnosis depends on histopathologic confirmation, which may lead to under-recognition. Early suspicion and individualized management are essential, though the optimal treatment approach for extrapulmonary infection remains undefined.</p></abstract><kwd-group><kwd><italic toggle="yes">Pneumocystis jirovecii</italic></kwd><kwd>extrapulmonary infection</kwd><kwd>bone marrow</kwd><kwd>AIDS</kwd><kwd>opportunistic infections</kwd><kwd>case report</kwd><kwd>pancytopenia</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-idr-17-00047"><title>1. Introduction</title><p><italic toggle="yes">Pneumocystis jirovecii</italic> (<italic toggle="yes">P. jirovecii</italic>) is an obligate fungal pathogen with parasitic behavior that colonizes the human respiratory tract and is primarily transmitted through airborne human-to-human contact. <italic toggle="yes">P. jirovecii</italic> can cause life-threatening pneumonia in individuals with impaired immunity such as those with advanced HIV/AIDS (particularly with CD4 counts &#x0003c;200 cells/&#x003bc;L), hematologic malignancies, solid organ transplants, or those receiving immunosuppressive therapies [<xref rid="B1-idr-17-00047" ref-type="bibr">1</xref>]. <italic toggle="yes">P. jirovecii</italic> pneumonia (PCP)&#x02014;still commonly referred to by the acronym PCP to maintain consistency across the literature&#x02014;remains a major opportunistic infection among people living with HIV, but its impact is increasingly recognized in non-HIV immunocompromised populations [<xref rid="B1-idr-17-00047" ref-type="bibr">1</xref>,<xref rid="B2-idr-17-00047" ref-type="bibr">2</xref>]. Genotyping studies have demonstrated that more than 90% of PCP cases involve genetically distinct mixtures of <italic toggle="yes">P. jirovecii</italic> strains, supporting the hypothesis that ongoing exposure and repeated inhalation from diverse sources&#x02014;rather than the reactivation of latent organisms&#x02014;is the primary mechanism driving PCP pathogenesis [<xref rid="B1-idr-17-00047" ref-type="bibr">1</xref>].</p><p>In recent years, PCP has emerged as a critical concern among patients with hematologic malignancies, solid tumors, organ transplants, and those receiving immunosuppressive therapies [<xref rid="B2-idr-17-00047" ref-type="bibr">2</xref>]. Unlike the subacute clinical course typically observed in HIV-positive individuals, PCP in non-HIV patients presents with a rapid onset and progression to respiratory failure, often within days. These patients frequently experience more severe hypoxemia, and a higher mortality rate compared to their HIV-infected counterparts. Diagnostic challenges are more pronounced in the non-HIV population due to a lower fungal burden. Radiologic findings also differ, ranging from classical diffuse ground-glass opacities to more sharply demarcated panlobular patterns [<xref rid="B2-idr-17-00047" ref-type="bibr">2</xref>]. Therapeutically, cotrimoxazole remains the first-line treatment; however, the optimal dosing and duration in non-HIV patients are not fully standardized. The benefit of adjunctive corticosteroids in this population also remains controversial [<xref rid="B2-idr-17-00047" ref-type="bibr">2</xref>]. Extrapulmonary infection by <italic toggle="yes">P. jirovecii</italic> is rare, with the lymph nodes and spleen being the most frequently affected sites [<xref rid="B3-idr-17-00047" ref-type="bibr">3</xref>]. Bone marrow involvement has been described only in a limited number of cases worldwide [<xref rid="B3-idr-17-00047" ref-type="bibr">3</xref>,<xref rid="B4-idr-17-00047" ref-type="bibr">4</xref>,<xref rid="B5-idr-17-00047" ref-type="bibr">5</xref>,<xref rid="B6-idr-17-00047" ref-type="bibr">6</xref>,<xref rid="B7-idr-17-00047" ref-type="bibr">7</xref>,<xref rid="B8-idr-17-00047" ref-type="bibr">8</xref>,<xref rid="B9-idr-17-00047" ref-type="bibr">9</xref>,<xref rid="B10-idr-17-00047" ref-type="bibr">10</xref>,<xref rid="B11-idr-17-00047" ref-type="bibr">11</xref>,<xref rid="B12-idr-17-00047" ref-type="bibr">12</xref>,<xref rid="B13-idr-17-00047" ref-type="bibr">13</xref>]. The primary risk factor associated with bone marrow infection is HIV/AIDS, particularly in patients who have not received adequate pharmacologic prophylaxis for <italic toggle="yes">P. jirovecii</italic>, such as systemic cotrimoxazole or dapsone. Inhaled pentamidine, although once widely used, has been associated with an increased risk of extrapulmonary disease due to insufficient systemic levels [<xref rid="B3-idr-17-00047" ref-type="bibr">3</xref>,<xref rid="B4-idr-17-00047" ref-type="bibr">4</xref>]. This stage of infection is believed to represent hematogenous or lymphatic dissemination from a primary pulmonary focus and carries a poor prognosis, with mortality rates reported to exceed 90% in several series [<xref rid="B3-idr-17-00047" ref-type="bibr">3</xref>,<xref rid="B4-idr-17-00047" ref-type="bibr">4</xref>,<xref rid="B5-idr-17-00047" ref-type="bibr">5</xref>,<xref rid="B6-idr-17-00047" ref-type="bibr">6</xref>,<xref rid="B7-idr-17-00047" ref-type="bibr">7</xref>,<xref rid="B8-idr-17-00047" ref-type="bibr">8</xref>,<xref rid="B9-idr-17-00047" ref-type="bibr">9</xref>,<xref rid="B10-idr-17-00047" ref-type="bibr">10</xref>,<xref rid="B11-idr-17-00047" ref-type="bibr">11</xref>,<xref rid="B12-idr-17-00047" ref-type="bibr">12</xref>]. In the comprehensive review by Ng et al., most cases of disseminated <italic toggle="yes">P. jirovecii</italic> with bone marrow involvement occurred in patients with primary pulmonary disease and were diagnosed postmortem [<xref rid="B13-idr-17-00047" ref-type="bibr">13</xref>]. Diagnosis typically relies on histopathologic examination, and in many instances, the condition is identified incidentally during the evaluation of tissue samples [<xref rid="B3-idr-17-00047" ref-type="bibr">3</xref>,<xref rid="B4-idr-17-00047" ref-type="bibr">4</xref>,<xref rid="B5-idr-17-00047" ref-type="bibr">5</xref>,<xref rid="B6-idr-17-00047" ref-type="bibr">6</xref>,<xref rid="B7-idr-17-00047" ref-type="bibr">7</xref>,<xref rid="B8-idr-17-00047" ref-type="bibr">8</xref>,<xref rid="B9-idr-17-00047" ref-type="bibr">9</xref>,<xref rid="B10-idr-17-00047" ref-type="bibr">10</xref>,<xref rid="B11-idr-17-00047" ref-type="bibr">11</xref>,<xref rid="B12-idr-17-00047" ref-type="bibr">12</xref>,<xref rid="B13-idr-17-00047" ref-type="bibr">13</xref>].</p><p>On the other hand, Kaposi sarcoma (KS) is a vascular tumor associated with human herpesvirus 8 (HHV-8) in patients living with HIV. It typically affects the skin, mucosa, and lymph nodes, but can also present with visceral dissemination, particularly involving the lungs and gastrointestinal tract, which worsens the prognosis [<xref rid="B14-idr-17-00047" ref-type="bibr">14</xref>]. KS may also be associated with hyperinflammatory syndromes such as immune reconstitution inflammatory syndrome (KS-IRIS) and inflammatory cytokine syndrome (KICS). KS-IRIS can present either by exacerbating pre-existing lesions or unmasking subclinical disease, often leading to rapid clinical deterioration. Unlike IRIS caused by other opportunistic infections, corticosteroids should be avoided in KS-IRIS due to the risk of accelerating viral replication and tumor progression [<xref rid="B14-idr-17-00047" ref-type="bibr">14</xref>]. KICS, a more recently recognized condition, is characterized by systemic inflammatory response syndrome (SIRS) with high levels of HHV-8 viremia and elevated interleukins (IL-6 and IL-10). Clinically, KICS often overlaps with multicentric Castleman disease (MCD), although without histological confirmation of MCD. KICS carries a high mortality rate and may occur concurrently with KS-IRIS, as both conditions are driven by immune dysregulation in the setting of viral replication. Prompt recognition and differentiation between these KS-driven complications are essential to guide appropriate management [<xref rid="B14-idr-17-00047" ref-type="bibr">14</xref>].</p><p>We present the case of an adult living with HIV who developed PCP, which subsequently progressed to disseminated disease with bone marrow involvement. During hospitalization, a concurrent diagnosis of KS affecting the skin and gastrointestinal tract was established, further complicating the clinical course. A summary of the patient&#x02019;s clinical presentation and laboratory findings is provided below.</p></sec><sec id="sec2-idr-17-00047"><title>2. Case Report</title><p>A 34-year-old man with a history of hypertension and unprotected sexual activity presented with a three-month history of fatigue, night sweats, an 11-pound involuntary weight loss, dry cough, intermittent non-dysenteric diarrhea, and progressive dyspnea. On examination, he was dehydrated, had an oxygen saturation of 78%, and exhibited oral lesions suggestive of candidiasis. Initial laboratories revealed mild thrombocytopenia, a positive four generation HIV test, reactive serologic tests for <italic toggle="yes">Treponema pallidum</italic>, and a blood arterial gas test with a moderate oxygenation disorder and a high alveolar&#x02013;arterial gradient (<xref rid="idr-17-00047-t001" ref-type="table">Table 1</xref>). A chest X-ray showed left basal interstitial opacities, later characterized on chest tomography, revealing extensive ground-glass opacities randomly distributed in both lung fields (<xref rid="idr-17-00047-f001" ref-type="fig">Figure 1</xref>).</p><p>The patient was considered to have a diagnosis of HIV infection, latent syphilis, oral candidiasis, and multilobar pneumonia of an undetermined etiology. The CD4 count was 33 cells/mm<sup>3</sup>, and the HIV viral load was 2,095,776 copies/mL. Due to the immunosuppressive condition and the tomographic pattern, a PCP was suspected. Antimicrobial therapy was started with fluconazole, benzathine penicillin, and cotrimoxazole with corticosteroids. The fibrobronchoscopy and bronchoalveolar lavage revealed structures suggestive of <italic toggle="yes">P. jirovecii</italic> (<xref rid="idr-17-00047-f002" ref-type="fig">Figure 2</xref>), confirming the diagnosis of severe PCP and ruling out other infectious conditions. Therapy with cotrimoxazole was continued at a dose of 20 mg/kg/day, based on the trimethoprim component, as well as prednisolone on a tapering regimen. After 12 days of hospitalization, the patient was discharged on oral cotrimoxazole and prednisolone for 21 days, with plans to initiate antiretroviral therapy as an outpatient. The platelet count continued to be low, and other opportunistic infections, such as tuberculosis and histoplasmosis, were ruled out (<xref rid="idr-17-00047-t002" ref-type="table">Table 2</xref>).</p><p>Five days after discharge, the patient was readmitted for persistent abdominal pain, diarrhea, emesis, and fever. On readmission, laboratory tests showed persistent thrombocytopenia, leukocytosis, neutrophilia, elevated C-reactive protein, and hyponatremia (<xref rid="idr-17-00047-t001" ref-type="table">Table 1</xref>). Stool samples were negative for parasitic, bacterial, or fungal infection, and abdominal computed tomography revealed splenomegaly and an inflammatory thickening of the distal ileum.</p><p>During hospitalization, the patient developed pancytopenia, prompting a bone marrow biopsy, which revealed foamy, amorphous eosinophilic material and small, non-budding round structures suggestive of <italic toggle="yes">P. jirovecii</italic> yeasts (<xref rid="idr-17-00047-f003" ref-type="fig">Figure 3</xref>), confirming disseminated infection with bone marrow involvement. A diagnosis of KS was confirmed by a histopathologic analysis of both a skin biopsy and an inguinal lymph node biopsy. Additionally, video capsule endoscopy revealed lesions consistent with KS involving the esophagus, duodenum, jejunum, and ileum. By that time, therapy with cotrimoxazole had been completed for a total of 21 days, with a progressive resolution of leukopenia and thrombocytopenia, and he was referred to an oncology institution to complete oncologic and antiretroviral treatment. Two months later, the patient was hospitalized again due to clinical deterioration, ultimately succumbing to multisystem organ failure.</p></sec><sec sec-type="discussion" id="sec3-idr-17-00047"><title>3. Discussion</title><p><italic toggle="yes">P. jirovecii</italic> infection presents in patients with immunosuppressive conditions such as AIDS, hematologic or solid organ malignancies, and iatrogenic immunosuppression [<xref rid="B1-idr-17-00047" ref-type="bibr">1</xref>,<xref rid="B2-idr-17-00047" ref-type="bibr">2</xref>]. This infection primarily affects the lungs, as the fungus adheres to and erodes type 1 pneumocytes, leading to diffuse alveolar damage [<xref rid="B15-idr-17-00047" ref-type="bibr">15</xref>]. In immunocompetent individuals, <italic toggle="yes">P. jirovecii</italic> colonization is typically asymptomatic and self-limited. This effective control is mediated through the coordinated activation of antigen-presenting cells, CD4+ T cells, and B cells within bronchus-associated lymphoid tissue. These structures facilitate communication between CD4+ T cells&#x02014;particularly follicular helper T cells&#x02014;and B cells, leading to M2 macrophage polarization and fungal clearance with minimal inflammation [<xref rid="B16-idr-17-00047" ref-type="bibr">16</xref>]. In contrast, immunocompromised hosts&#x02014;especially those with CD4+ T cell depletion&#x02014;fail to mount this organized response. The fungus proliferates in the alveoli, triggering a poorly regulated, pro-inflammatory reaction. In this context, CD8+ cytotoxic T cells, NK cells, and pro-inflammatory Th1 responses predominate, promoting M1 macrophage activation through IFN-&#x003b3; and TNF-&#x003b1;. While these pathways enhance fungal clearance, they also contribute significantly to pulmonary inflammation and tissue damage. Furthermore, <italic toggle="yes">P. jirovecii</italic> surface antigens such as major surface glycoprotein (Msg) and &#x003b2;-D-glucan stimulate Toll-like and C-type lectin receptors, enhancing local inflammation and impairing surfactant production, thus compromising alveolar integrity and gas exchange [<xref rid="B16-idr-17-00047" ref-type="bibr">16</xref>,<xref rid="B17-idr-17-00047" ref-type="bibr">17</xref>].</p><p>The most common symptoms are dry cough, progressive dyspnea, fever, and low exercise tolerance [<xref rid="B15-idr-17-00047" ref-type="bibr">15</xref>,<xref rid="B18-idr-17-00047" ref-type="bibr">18</xref>]. The incubation period from infection to the onset of clinical disease is approximately 5 to 6 days but sometimes can be extended up to 28 days [<xref rid="B15-idr-17-00047" ref-type="bibr">15</xref>]. Upon consultation, most patients present with hypoxemia, a high alveolar&#x02013;arterial gradient, and in some cases, respiratory failure [<xref rid="B15-idr-17-00047" ref-type="bibr">15</xref>,<xref rid="B18-idr-17-00047" ref-type="bibr">18</xref>].</p><p>Diagnosing PCP requires a susceptible immunosuppressed host with a compatible clinical syndrome, and suggestive laboratory and imaging findings [<xref rid="B19-idr-17-00047" ref-type="bibr">19</xref>]. Chest computed tomography is the imaging modality of choice and usually reveals diffuse ground glass lung opacities, sometimes accompanied by lobar consolidations and subpleural compromise. In contrast, other less frequent tomographic findings, such as cysts or pneumothorax, can also be found [<xref rid="B19-idr-17-00047" ref-type="bibr">19</xref>,<xref rid="B20-idr-17-00047" ref-type="bibr">20</xref>]. Laboratory diagnosis usually relies on indirect methods such as a measurement of serum lactate dehydrogenase [LDH] which is elevated in most cases of PCP in people living with HIV, due to its release from damaged lung tissue [<xref rid="B19-idr-17-00047" ref-type="bibr">19</xref>,<xref rid="B21-idr-17-00047" ref-type="bibr">21</xref>]. A sensitivity and specificity of 86% and 45.3% have been described, with a cut-off point of 268 UI/L [<xref rid="B19-idr-17-00047" ref-type="bibr">19</xref>,<xref rid="B21-idr-17-00047" ref-type="bibr">21</xref>]. Because <italic toggle="yes">P. jirovecii</italic> cannot be cultured ex-vivo, diagnosis depends on a direct visualization of the fungus or molecular detection of its DNA [<xref rid="B19-idr-17-00047" ref-type="bibr">19</xref>,<xref rid="B21-idr-17-00047" ref-type="bibr">21</xref>]. Currently, the gold standard method is the analysis of bronchoalveolar lavage, with a reported sensitivity of 95&#x02013;100% [<xref rid="B15-idr-17-00047" ref-type="bibr">15</xref>,<xref rid="B19-idr-17-00047" ref-type="bibr">19</xref>,<xref rid="B21-idr-17-00047" ref-type="bibr">21</xref>]. A diagnosis can be made with the observation of the trophic or cystic forms with special stains such as Giemsa, Wright, Diff-Quik, Cresyl violet or Grocott&#x02013;G&#x000f6;m&#x000f6;ri&#x02019;s methenamine silver; however, a diagnostic can also be made by the presence of eosinophilic amorphous exudates in the alveolar spaces, which can be observed with routine staining [<xref rid="B15-idr-17-00047" ref-type="bibr">15</xref>,<xref rid="B19-idr-17-00047" ref-type="bibr">19</xref>,<xref rid="B21-idr-17-00047" ref-type="bibr">21</xref>]. Specimens obtained through other techniques such as expectorated sputum, or induced sputum have a lower and variable performance [<xref rid="B19-idr-17-00047" ref-type="bibr">19</xref>,<xref rid="B21-idr-17-00047" ref-type="bibr">21</xref>]. The molecular diagnosis of PCP is based on detecting several gene loci with polymerase chain reaction [PCR] techniques, and performance improves by using multicopy targets such as Msg, mtLSU, HSP70, and cdc2 [<xref rid="B22-idr-17-00047" ref-type="bibr">22</xref>]. The sensitivity of these techniques can be improved by using nested PCR (nPCR). Since the fungus can colonize the airways without establishing infection, the specificity can be also improved with the use of quantitative PCR (qPCR), which can be performed on invasive and non-invasive specimens [<xref rid="B22-idr-17-00047" ref-type="bibr">22</xref>]. In people living with HIV, the detection of HSP70 by qPCR on bronchoalveolar lavage reported a sensitivity and specificity of 98% and 96%, respectively [<xref rid="B23-idr-17-00047" ref-type="bibr">23</xref>], and the detection of Msg by qPCR on oral wash reported a sensitivity and specificity of 88% and 85%, respectively [<xref rid="B24-idr-17-00047" ref-type="bibr">24</xref>]. A negative PCR will likely exclude PCP, especially in deep respiratory samples [<xref rid="B25-idr-17-00047" ref-type="bibr">25</xref>], but a positive PCR requires clinical interpretation to distinguish between colonization and active infection, and there is still a need for more research to validate and establish specific cut-off points for these molecular techniques [<xref rid="B19-idr-17-00047" ref-type="bibr">19</xref>,<xref rid="B22-idr-17-00047" ref-type="bibr">22</xref>,<xref rid="B25-idr-17-00047" ref-type="bibr">25</xref>].</p><p>Extrapulmonary infection by <italic toggle="yes">P. jirovecii</italic> is rare and the manifestations depend on the compromised organ [<xref rid="B3-idr-17-00047" ref-type="bibr">3</xref>]. The most commonly affected sites are the lymph nodes, liver, spleen, gastrointestinal tract, and bone marrow; with 64% of these cases reporting multiple organ involvement [<xref rid="B3-idr-17-00047" ref-type="bibr">3</xref>]. Excluding the bone marrow, tomographic studies often reveal hypodense lesions with a tendency to calcify on the affected organs, which progress to rimmed or complete calcifications after successful treatment [<xref rid="B3-idr-17-00047" ref-type="bibr">3</xref>]. The primary risk factor for developing an extrapulmonary infection is the AIDS stage of HIV infection, especially those patients who do not receive adequate prophylaxis with cotrimoxazole or receive other pharmacological regimens such as inhaled pentamidine [<xref rid="B3-idr-17-00047" ref-type="bibr">3</xref>,<xref rid="B4-idr-17-00047" ref-type="bibr">4</xref>,<xref rid="B9-idr-17-00047" ref-type="bibr">9</xref>,<xref rid="B10-idr-17-00047" ref-type="bibr">10</xref>,<xref rid="B12-idr-17-00047" ref-type="bibr">12</xref>]. Other risk factors include hypogammaglobulinemia and hematologic malignancies [<xref rid="B3-idr-17-00047" ref-type="bibr">3</xref>,<xref rid="B23-idr-17-00047" ref-type="bibr">23</xref>].</p><p>The mechanism by which <italic toggle="yes">P. jirovecii</italic> reaches the bone marrow remains unclear. Almost all patients with bone marrow compromise had a pulmonary infection first, which strongly suggests that the fungus reaches the bloodstream from the lungs [<xref rid="B3-idr-17-00047" ref-type="bibr">3</xref>,<xref rid="B5-idr-17-00047" ref-type="bibr">5</xref>,<xref rid="B6-idr-17-00047" ref-type="bibr">6</xref>,<xref rid="B7-idr-17-00047" ref-type="bibr">7</xref>,<xref rid="B8-idr-17-00047" ref-type="bibr">8</xref>,<xref rid="B10-idr-17-00047" ref-type="bibr">10</xref>,<xref rid="B11-idr-17-00047" ref-type="bibr">11</xref>,<xref rid="B12-idr-17-00047" ref-type="bibr">12</xref>]. It is believed that in severely immunosuppressed hosts, the microorganism reaches the pulmonary lymph nodes, escapes phagocytosis, and disseminates into the venous bloodstream through the efferent lymphatic drainage [<xref rid="B5-idr-17-00047" ref-type="bibr">5</xref>]. Alternatively, some histologic evidence suggests a possible mechanism through alveolar septal destruction and direct capillary wall invasion [<xref rid="B5-idr-17-00047" ref-type="bibr">5</xref>]. Upon reaching the bloodstream, the bone marrow compromise may represent just a stage of a disseminated infection, like what happens in miliary tuberculosis [<xref rid="B5-idr-17-00047" ref-type="bibr">5</xref>,<xref rid="B26-idr-17-00047" ref-type="bibr">26</xref>].</p><p>To our knowledge, bone marrow infection by <italic toggle="yes">P. jirovecii</italic> has been reported in only a small number of cases worldwide (<xref rid="idr-17-00047-t003" ref-type="table">Table 3</xref>) [<xref rid="B3-idr-17-00047" ref-type="bibr">3</xref>,<xref rid="B4-idr-17-00047" ref-type="bibr">4</xref>,<xref rid="B5-idr-17-00047" ref-type="bibr">5</xref>,<xref rid="B6-idr-17-00047" ref-type="bibr">6</xref>,<xref rid="B7-idr-17-00047" ref-type="bibr">7</xref>,<xref rid="B8-idr-17-00047" ref-type="bibr">8</xref>,<xref rid="B9-idr-17-00047" ref-type="bibr">9</xref>,<xref rid="B10-idr-17-00047" ref-type="bibr">10</xref>,<xref rid="B11-idr-17-00047" ref-type="bibr">11</xref>,<xref rid="B12-idr-17-00047" ref-type="bibr">12</xref>]. In our review, 63.6% of the affected patients were living with AIDS [<xref rid="B3-idr-17-00047" ref-type="bibr">3</xref>,<xref rid="B5-idr-17-00047" ref-type="bibr">5</xref>,<xref rid="B6-idr-17-00047" ref-type="bibr">6</xref>,<xref rid="B8-idr-17-00047" ref-type="bibr">8</xref>,<xref rid="B9-idr-17-00047" ref-type="bibr">9</xref>,<xref rid="B10-idr-17-00047" ref-type="bibr">10</xref>,<xref rid="B11-idr-17-00047" ref-type="bibr">11</xref>,<xref rid="B12-idr-17-00047" ref-type="bibr">12</xref>], while the remainder had various forms of lymphoma [<xref rid="B4-idr-17-00047" ref-type="bibr">4</xref>,<xref rid="B7-idr-17-00047" ref-type="bibr">7</xref>]. The mean age was 42 years, and 81.8% of the cases occurred in male patients. [<xref rid="B3-idr-17-00047" ref-type="bibr">3</xref>,<xref rid="B4-idr-17-00047" ref-type="bibr">4</xref>,<xref rid="B5-idr-17-00047" ref-type="bibr">5</xref>,<xref rid="B6-idr-17-00047" ref-type="bibr">6</xref>,<xref rid="B7-idr-17-00047" ref-type="bibr">7</xref>,<xref rid="B8-idr-17-00047" ref-type="bibr">8</xref>,<xref rid="B9-idr-17-00047" ref-type="bibr">9</xref>,<xref rid="B10-idr-17-00047" ref-type="bibr">10</xref>,<xref rid="B11-idr-17-00047" ref-type="bibr">11</xref>,<xref rid="B12-idr-17-00047" ref-type="bibr">12</xref>]. The most frequent symptoms were dyspnea (45.4%) and fever (36.3%). Blood cytopenias such as anemia, leukopenia, and thrombocytopenia were described in almost all of these cases [<xref rid="B3-idr-17-00047" ref-type="bibr">3</xref>,<xref rid="B4-idr-17-00047" ref-type="bibr">4</xref>,<xref rid="B5-idr-17-00047" ref-type="bibr">5</xref>,<xref rid="B7-idr-17-00047" ref-type="bibr">7</xref>,<xref rid="B8-idr-17-00047" ref-type="bibr">8</xref>,<xref rid="B10-idr-17-00047" ref-type="bibr">10</xref>,<xref rid="B12-idr-17-00047" ref-type="bibr">12</xref>], as well as primary pulmonary infection, which supports the hypothesis that <italic toggle="yes">P. jirovecii</italic> reaches the bloodstream from the lungs through the efferent lymphatic drainage after escaping phagocytosis, or by a direct invasion of capillaries [<xref rid="B3-idr-17-00047" ref-type="bibr">3</xref>,<xref rid="B5-idr-17-00047" ref-type="bibr">5</xref>,<xref rid="B6-idr-17-00047" ref-type="bibr">6</xref>,<xref rid="B7-idr-17-00047" ref-type="bibr">7</xref>,<xref rid="B8-idr-17-00047" ref-type="bibr">8</xref>,<xref rid="B10-idr-17-00047" ref-type="bibr">10</xref>,<xref rid="B11-idr-17-00047" ref-type="bibr">11</xref>,<xref rid="B12-idr-17-00047" ref-type="bibr">12</xref>]. All these cases were diagnosed with a histologic examination of the bone marrow, and the most frequent findings were the presence of amorphous eosinophilic exudates or <italic toggle="yes">P. jirovecii</italic> cysts [<xref rid="B3-idr-17-00047" ref-type="bibr">3</xref>,<xref rid="B4-idr-17-00047" ref-type="bibr">4</xref>,<xref rid="B5-idr-17-00047" ref-type="bibr">5</xref>,<xref rid="B6-idr-17-00047" ref-type="bibr">6</xref>,<xref rid="B7-idr-17-00047" ref-type="bibr">7</xref>,<xref rid="B8-idr-17-00047" ref-type="bibr">8</xref>,<xref rid="B10-idr-17-00047" ref-type="bibr">10</xref>,<xref rid="B11-idr-17-00047" ref-type="bibr">11</xref>,<xref rid="B12-idr-17-00047" ref-type="bibr">12</xref>]. Treatment regimens were variable, and a high mortality rate greater than 90% was described despite treatment [<xref rid="B3-idr-17-00047" ref-type="bibr">3</xref>,<xref rid="B4-idr-17-00047" ref-type="bibr">4</xref>,<xref rid="B5-idr-17-00047" ref-type="bibr">5</xref>,<xref rid="B6-idr-17-00047" ref-type="bibr">6</xref>,<xref rid="B7-idr-17-00047" ref-type="bibr">7</xref>,<xref rid="B8-idr-17-00047" ref-type="bibr">8</xref>,<xref rid="B9-idr-17-00047" ref-type="bibr">9</xref>,<xref rid="B10-idr-17-00047" ref-type="bibr">10</xref>,<xref rid="B11-idr-17-00047" ref-type="bibr">11</xref>,<xref rid="B12-idr-17-00047" ref-type="bibr">12</xref>].</p><p>In this case, while the diagnosis of disseminated <italic toggle="yes">P. jirovecii</italic> infection was confirmed histologically through bone marrow biopsy, the subsequent clinical deterioration and death raise the possibility of additional or alternative diagnoses. One potential contributor is KS-IRIS, particularly if antiretroviral therapy was initiated after discharge. KS-IRIS is known to present with a rapid progression of KS lesions and systemic inflammatory features, particularly in the presence of pulmonary involvement, which carries a poor prognosis. Another possible diagnosis is KICS, a hyperinflammatory state driven by HHV-8 replication that often overlaps clinically with multicentric Castleman disease [<xref rid="B14-idr-17-00047" ref-type="bibr">14</xref>]. KICS is characterized by features such as pancytopenia, SIRS, and hyponatremia, all of which were present in this case. Additionally, hemophagocytic lymphohistiocytosis (HLH) must be considered. HLH is a hyperinflammatory syndrome that can occur in the setting of HIV, opportunistic infections, or malignancies such as KS. The presence of persistent fever, pancytopenia, liver dysfunction, and inflammatory markers raises clinical suspicion [<xref rid="B27-idr-17-00047" ref-type="bibr">27</xref>]. However, we lacked key diagnostic parameters such as ferritin, triglycerides, and soluble IL-2 receptor levels, and hemophagocytosis was not documented in the bone marrow biopsy which lowers the probability. These conditions may account for the patient&#x02019;s rapid clinical decline despite appropriate antimicrobial therapy and are supported by rising inflammatory markers such as leukocytosis and elevated C-reactive protein levels.</p><p>Unfortunately, due to the patient&#x02019;s transfer to another institution, we did not have access to clinical records from the final hospitalization, and no autopsy was performed. Thus, we were unable to confirm whether ART had been initiated, or whether there were additional clinical, laboratory, or imaging findings that might have supported a diagnosis of KS-IRIS or KICS. These limitations preclude definitive conclusions regarding the cause of death and highlight the diagnostic complexity in severely immunocompromised patients with overlapping opportunistic infections and malignancies.</p><p>Our case shares several features with the few reported instances of <italic toggle="yes">P. jirovecii</italic> involvement of the bone marrow in patients with advanced AIDS. As in previous reports, the patient exhibited profound immunosuppression, with a markedly low CD4 count and a high HIV viral load&#x02014;both recognized risk factors for extrapulmonary dissemination. Notably, bone marrow involvement in our case was confirmed antemortem via bone marrow biopsy, whereas most previously documented cases were identified postmortem, often incidentally. This distinction reinforces the notion that disseminated <italic toggle="yes">P. jirovecii</italic> infection involving the bone marrow is likely underdiagnosed during life, particularly in the absence of targeted histopathologic evaluation.</p></sec><sec sec-type="conclusions" id="sec4-idr-17-00047"><title>4. Conclusions</title><p><italic toggle="yes">P. jirovecii</italic> infection typically presents as pulmonary disease but may occasionally disseminate to extrapulmonary sites such as the bone marrow, particularly in patients with advanced immunosuppression. Bone marrow involvement is an uncommon but clinically significant finding that is usually identified through histopathologic evaluation and is associated with a high mortality.</p><p>This case contributes to the limited literature on disseminated <italic toggle="yes">P. jirovecii</italic> infection and highlights the importance of considering bone marrow involvement in people living with HIV who present with PCP and unexplained cytopenias. To date, no clinical trials have defined optimal treatment strategies for extrapulmonary or disseminated <italic toggle="yes">P. jirovecii</italic> infection, and it remains uncertain whether the standard 21-day cotrimoxazole regimen for pulmonary disease is adequate in these scenarios. Ongoing clinical awareness, histopathologic confirmation when feasible, and individualized clinical judgment remain essential in managing these rare and challenging presentations.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors are grateful to the reviewers, the editorial board at Infectious Disease Reports, the Hospital Universitario de la Samaritana, the National University of Colombia and Cl&#x000ed;nica Colsanitas S.A. for their support.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, D.A.C.-D.; methodology, D.A.C.-D. and V.N.-L.; formal analysis, D.A.C.-D.; investigation, V.N.-L.; resources, C.A.&#x000c1;.-M.; writing&#x02014;original draft preparation, V.N.-L.; writing&#x02014;review and editing D.A.C.-D. and C.A.&#x000c1;.-M.; visualization C.M.C.-V.; supervision, V.P.-H.; project administration, V.P.-H. and J.P.L.-S.; funding acquisition, C.A.&#x000c1;.-M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Hospital Universitario de la Samaritana. Code No 04-2023 date of approval 30 May 2023.</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patient to publish this paper.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>All relevant information has been presented in the case report. Any additional data may be made available on reasonable request from the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">AIDS</td><td align="left" valign="middle" rowspan="1" colspan="1">Acquired immunodeficiency syndrome</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CMV</td><td align="left" valign="middle" rowspan="1" colspan="1">Cytomegalovirus</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DNA</td><td align="left" valign="middle" rowspan="1" colspan="1">Deoxyribonucleic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GMS</td><td align="left" valign="middle" rowspan="1" colspan="1">Grocott&#x02013;G&#x000f6;m&#x000f6;ri&#x02019;s methenamine silver</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">H-E</td><td align="left" valign="middle" rowspan="1" colspan="1">Hematoxylin and eosin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HHV-8</td><td align="left" valign="middle" rowspan="1" colspan="1">Human herpesvirus 8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HIV</td><td align="left" valign="middle" rowspan="1" colspan="1">Human immunodeficiency virus</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HLH</td><td align="left" valign="middle" rowspan="1" colspan="1">Hemophagocytic lymphohistiocytosis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">KS</td><td align="left" valign="middle" rowspan="1" colspan="1">Kaposi&#x02019;s sarcoma</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LDH</td><td align="left" valign="middle" rowspan="1" colspan="1">Lactate dehydrogenase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MCD</td><td align="left" valign="middle" rowspan="1" colspan="1">Multicentric Castleman disease</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Msg</td><td align="left" valign="middle" rowspan="1" colspan="1">Major surface glycoprotein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">nPCR</td><td align="left" valign="middle" rowspan="1" colspan="1">Nested Polymerase chain reaction</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PAS</td><td align="left" valign="middle" rowspan="1" colspan="1">Periodic Acid Schiff</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PCP</td><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Pneumocystis jirovecii</italic> pneumonia</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PCR</td><td align="left" valign="middle" rowspan="1" colspan="1">Polymerase chain reaction</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">P. Jirovecii</italic></td><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Pneumocystis jirovecii</italic></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SIRS</td><td align="left" valign="middle" rowspan="1" colspan="1">Systemic inflammatory response syndrome</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">qPCR</td><td align="left" valign="middle" rowspan="1" colspan="1">Quantitative Polymerase chain reaction</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VDRL</td><td align="left" valign="middle" rowspan="1" colspan="1">Venereal Disease Research Laboratory</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-idr-17-00047"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alanio</surname><given-names>A.</given-names></name>
<name><surname>Bretagne</surname><given-names>S.</given-names></name>
</person-group><article-title>Pneumocystis jirovecii detection in asymptomatic patients: What does its natural history tell us?</article-title><source>F1000Research</source><year>2017</year><volume>6</volume><fpage>739</fpage><pub-id pub-id-type="doi">10.12688/f1000research.10619.1</pub-id><pub-id pub-id-type="pmid">28649366</pub-id>
</element-citation></ref><ref id="B2-idr-17-00047"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tasaka</surname><given-names>S.</given-names></name>
<name><surname>Tokuda</surname><given-names>H.</given-names></name>
</person-group><article-title>Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies</article-title><source>J. Infect. Chemother. Off. J. Jpn. Soc. Chemother.</source><year>2012</year><volume>18</volume><fpage>793</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1007/s10156-012-0453-0</pub-id><pub-id pub-id-type="pmid">22864454</pub-id>
</element-citation></ref><ref id="B3-idr-17-00047"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Telzak</surname><given-names>E.E.</given-names></name>
<name><surname>Cote</surname><given-names>R.J.</given-names></name>
<name><surname>Gold</surname><given-names>J.W.M.</given-names></name>
<name><surname>Campbell</surname><given-names>S.W.</given-names></name>
<name><surname>Armstrong</surname><given-names>D.</given-names></name>
</person-group><article-title>Extrapulmonary Pneumocystis carinii Infections</article-title><source>Clin. Infect. Dis.</source><year>1990</year><volume>12</volume><fpage>380</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1093/clinids/12.3.380</pub-id><pub-id pub-id-type="pmid">2193343</pub-id>
</element-citation></ref><ref id="B4-idr-17-00047"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grier</surname><given-names>D.D.</given-names></name>
<name><surname>Lewis</surname><given-names>Z.</given-names></name>
<name><surname>Palavecino</surname><given-names>E.L.</given-names></name>
</person-group><article-title>Bone marrow involvement by Pneumocystis jiroveci</article-title><source>Br. J. Haematol.</source><year>2009</year><volume>145</volume><fpage>149</fpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.2008.07438.x</pub-id><pub-id pub-id-type="pmid">19533848</pub-id>
</element-citation></ref><ref id="B5-idr-17-00047"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heyman</surname><given-names>M.R.</given-names></name>
<name><surname>Rasmussen</surname><given-names>P.</given-names></name>
</person-group><article-title>Pneumocystis carinii Involvement of the Bone Marrow in Acquired Immunodeficiency Syndrome</article-title><source>Am. J. Clin. Pathol.</source><year>1987</year><volume>87</volume><fpage>780</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.1093/ajcp/87.6.780</pub-id><pub-id pub-id-type="pmid">3035916</pub-id>
</element-citation></ref><ref id="B6-idr-17-00047"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rossi</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Pneumocystis carinii Infection of Bone Marrow in Patients With Malignant Lymphoma and Acquired Immunodeficiency Syndrome: Original Report of Three Cases</article-title><source>Arch. Intern. Med.</source><year>1990</year><volume>150</volume><fpage>450</fpage><pub-id pub-id-type="doi">10.1001/archinte.1990.00390140146030</pub-id><pub-id pub-id-type="pmid">2302020</pub-id>
</element-citation></ref><ref id="B7-idr-17-00047"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rossi</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Pneumocystis carinii in Bone Marrow</article-title><source>Ann. Intern. Med.</source><year>1985</year><volume>102</volume><fpage>868</fpage><pub-id pub-id-type="doi">10.7326/0003-4819-102-6-868_1</pub-id></element-citation></ref><ref id="B8-idr-17-00047"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Unger</surname><given-names>P.D.</given-names></name>
<name><surname>Rosenblum</surname><given-names>M.</given-names></name>
<name><surname>Krown</surname><given-names>S.E.</given-names></name>
</person-group><article-title>Disseminated Pneumocystis carinii infection in a patient with acquired immunodeficiency syndrome</article-title><source>Hum. Pathol.</source><year>1988</year><volume>19</volume><fpage>113</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/S0046-8177(88)80327-7</pub-id><pub-id pub-id-type="pmid">3257197</pub-id>
</element-citation></ref><ref id="B9-idr-17-00047"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lubat</surname><given-names>E.</given-names></name>
<name><surname>Megibow</surname><given-names>A.J.</given-names></name>
<name><surname>Balthazar</surname><given-names>E.J.</given-names></name>
<name><surname>Goldenberg</surname><given-names>A.S.</given-names></name>
<name><surname>Birnbaum</surname><given-names>B.A.</given-names></name>
<name><surname>Bosniak</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Extrapulmonary Pneumocystis carinii infection in AIDS: CT findings</article-title><source>Radiology</source><year>1990</year><volume>174</volume><fpage>157</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1148/radiology.174.1.2294543</pub-id><pub-id pub-id-type="pmid">2294543</pub-id>
</element-citation></ref><ref id="B10-idr-17-00047"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amin</surname><given-names>M.B.</given-names></name>
<name><surname>Abrash</surname><given-names>M.P.</given-names></name>
<name><surname>Mezger</surname><given-names>E.</given-names></name>
<name><surname>Sekerak</surname><given-names>G.F.</given-names></name>
</person-group><article-title>Systemic Dissemination of Pneumocystis Carinii in a Patient with Acquired Immunodeficiency Syndrome</article-title><source>Henry Ford Hosp. Med. J.</source><year>1990</year><volume>38</volume><fpage>68</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">2228716</pub-id>
</element-citation></ref><ref id="B11-idr-17-00047"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Momose</surname><given-names>H.</given-names></name>
</person-group><article-title>Pneumocystis carinii as Foamy Exudate in Bone Marrow</article-title><source>JAMA J. Am. Med. Assoc.</source><year>1991</year><volume>265</volume><fpage>1672</fpage><pub-id pub-id-type="doi">10.1001/jama.1991.03460130062011</pub-id></element-citation></ref><ref id="B12-idr-17-00047"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lerdlamyong</surname><given-names>K.</given-names></name>
<name><surname>Sukpanichnant</surname><given-names>S.</given-names></name>
<name><surname>Rattanaumpawan</surname><given-names>P.</given-names></name>
</person-group><article-title>Bone marrow infection by Pneumocystis jirovecii</article-title><source>Br. J. Haematol.</source><year>2017</year><volume>176</volume><fpage>849</fpage><pub-id pub-id-type="doi">10.1111/bjh.14499</pub-id><pub-id pub-id-type="pmid">28106902</pub-id>
</element-citation></ref><ref id="B13-idr-17-00047"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ng</surname><given-names>V.L.</given-names></name>
<name><surname>Yajko</surname><given-names>D.M.</given-names></name>
<name><surname>Hadley</surname><given-names>W.K.</given-names></name>
</person-group><article-title>Extrapulmonary pneumocystosis</article-title><source>Clin. Microbiol. Rev.</source><year>1997</year><volume>10</volume><fpage>401</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1128/CMR.10.3.401</pub-id><pub-id pub-id-type="pmid">9227859</pub-id>
</element-citation></ref><ref id="B14-idr-17-00047"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dumic</surname><given-names>I.</given-names></name>
<name><surname>Radovanovic</surname><given-names>M.</given-names></name>
<name><surname>Igandan</surname><given-names>O.</given-names></name>
<name><surname>Savic</surname><given-names>I.</given-names></name>
<name><surname>Nordstrom</surname><given-names>C.W.</given-names></name>
<name><surname>Jevtic</surname><given-names>D.</given-names></name>
<name><surname>Subramanian</surname><given-names>A.</given-names></name>
<name><surname>Ramanan</surname><given-names>P.</given-names></name>
</person-group><article-title>A Fatal Case of Kaposi Sarcoma Immune Reconstitution Syndrome (KS-IRIS) Complicated by Kaposi Sarcoma Inflammatory Cytokine Syndrome (KICS) or Multicentric Castleman Disease (MCD): A Case Report and Review</article-title><source>Am. J. Case Rep.</source><year>2020</year><volume>21</volume><fpage>e926433-1</fpage><lpage>e926433-7</lpage><pub-id pub-id-type="doi">10.12659/AJCR.926433</pub-id><pub-id pub-id-type="pmid">33268763</pub-id>
</element-citation></ref><ref id="B15-idr-17-00047"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ibrahim</surname><given-names>A.</given-names></name>
<name><surname>Chattaraj</surname><given-names>A.</given-names></name>
<name><surname>Iqbal</surname><given-names>Q.</given-names></name>
<name><surname>Anjum</surname><given-names>A.</given-names></name>
<name><surname>Rehman</surname><given-names>M.E.U.</given-names></name>
<name><surname>Aijaz</surname><given-names>Z.</given-names></name>
<name><surname>Nasir</surname><given-names>F.</given-names></name>
<name><surname>Ansar</surname><given-names>S.</given-names></name>
<name><surname>Zangeneh</surname><given-names>T.T.</given-names></name>
<name><surname>Iftikhar</surname><given-names>A.</given-names></name>
</person-group><article-title>Pneumocystis jiroveci Pneumonia: A Review of Management in Human Immunodeficiency Virus (HIV) and Non-HIV Immunocompromised Patients</article-title><source>Avicenna J. Med.</source><year>2023</year><volume>13</volume><fpage>23</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1055/s-0043-1764375</pub-id><pub-id pub-id-type="pmid">36969352</pub-id>
</element-citation></ref><ref id="B16-idr-17-00047"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Charpentier</surname><given-names>E.</given-names></name>
<name><surname>M&#x000e9;nard</surname><given-names>S.</given-names></name>
<name><surname>Marques</surname><given-names>C.</given-names></name>
<name><surname>Berry</surname><given-names>A.</given-names></name>
<name><surname>Iriart</surname><given-names>X.</given-names></name>
</person-group><article-title>Immune Response in Pneumocystis Infections According to the Host Immune System Status</article-title><source>J. Fungi</source><year>2021</year><volume>7</volume><elocation-id>625</elocation-id><pub-id pub-id-type="doi">10.3390/jof7080625</pub-id></element-citation></ref><ref id="B17-idr-17-00047"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Castro</surname><given-names>J.</given-names></name>
<name><surname>Morrison-Bryant</surname><given-names>M.</given-names></name>
</person-group><article-title>Management of Pneumocystis Jirovecii pneumonia in HIV infected patients: Current options, challenges and future directions</article-title><source>HIVAIDS-Res. Palliat. Care</source><year>2010</year><volume>2</volume><fpage>123</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.2147/HIV.S7720</pub-id></element-citation></ref><ref id="B18-idr-17-00047"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fujii</surname><given-names>T.</given-names></name>
<name><surname>Iwamoto</surname><given-names>A.</given-names></name>
<name><surname>Nakamura</surname><given-names>T.</given-names></name>
<name><surname>Iwamoto</surname><given-names>A.</given-names></name>
<name><surname>Iwamoto</surname><given-names>A.</given-names></name>
<name><surname>Iwamoto</surname><given-names>A.</given-names></name>
</person-group><article-title>Pneumocystis pneumonia in patients with HIV infection: Clinical manifestations, laboratory findings, and radiological features</article-title><source>J. Infect. Chemother.</source><year>2007</year><volume>13</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1007/s10156-006-0484-5</pub-id><pub-id pub-id-type="pmid">17334722</pub-id>
</element-citation></ref><ref id="B19-idr-17-00047"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weyant</surname><given-names>R.B.</given-names></name>
<name><surname>Kabbani</surname><given-names>D.</given-names></name>
<name><surname>Doucette</surname><given-names>K.</given-names></name>
<name><surname>Lau</surname><given-names>C.</given-names></name>
<name><surname>Cervera</surname><given-names>C.</given-names></name>
</person-group><article-title>Pneumocystis jirovecii: A review with a focus on prevention and treatment</article-title><source>Expert Opin. Pharmacother.</source><year>2021</year><volume>22</volume><fpage>1579</fpage><lpage>1592</lpage><pub-id pub-id-type="doi">10.1080/14656566.2021.1915989</pub-id><pub-id pub-id-type="pmid">33870843</pub-id>
</element-citation></ref><ref id="B20-idr-17-00047"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>White</surname><given-names>P.L.</given-names></name>
<name><surname>Price</surname><given-names>J.S.</given-names></name>
<name><surname>Backx</surname><given-names>M.</given-names></name>
</person-group><article-title>Pneumocystis jirovecii Pneumonia: Epidemiology, Clinical Manifestation and Diagnosis</article-title><source>Curr. Fungal Infect. Rep.</source><year>2019</year><volume>13</volume><fpage>260</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1007/s12281-019-00349-3</pub-id></element-citation></ref><ref id="B21-idr-17-00047"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cruciani</surname><given-names>M.</given-names></name>
<name><surname>Marcati</surname><given-names>P.</given-names></name>
<name><surname>Malena</surname><given-names>M.</given-names></name>
<name><surname>Bosco</surname><given-names>O.</given-names></name>
<name><surname>Serpelloni</surname><given-names>G.</given-names></name>
<name><surname>Mengoli</surname><given-names>C.</given-names></name>
</person-group><article-title>Meta-analysis of diagnostic procedures for Pneumocystis carinii pneumonia in HIV-1-infected patients</article-title><source>Eur. Respir. J.</source><year>2002</year><volume>20</volume><fpage>982</fpage><lpage>989</lpage><pub-id pub-id-type="doi">10.1183/09031936.02.01372002</pub-id><pub-id pub-id-type="pmid">12412693</pub-id>
</element-citation></ref><ref id="B22-idr-17-00047"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morris</surname><given-names>A.</given-names></name>
<name><surname>Norris</surname><given-names>K.A.</given-names></name>
</person-group><article-title>Colonization by Pneumocystis jirovecii and Its Role in Disease</article-title><source>Clin. Microbiol. Rev.</source><year>2012</year><volume>25</volume><fpage>297</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1128/CMR.00013-12</pub-id><pub-id pub-id-type="pmid">22491773</pub-id>
</element-citation></ref><ref id="B23-idr-17-00047"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huggett</surname><given-names>J.F.</given-names></name>
<name><surname>Taylor</surname><given-names>M.S.</given-names></name>
<name><surname>Kocjan</surname><given-names>G.</given-names></name>
<name><surname>Evans</surname><given-names>H.E.</given-names></name>
<name><surname>Morris-Jones</surname><given-names>S.</given-names></name>
<name><surname>Gant</surname><given-names>V.</given-names></name>
<name><surname>Novak</surname><given-names>T.</given-names></name>
<name><surname>Costello</surname><given-names>A.M.</given-names></name>
<name><surname>Zumla</surname><given-names>A.</given-names></name>
<name><surname>Miller</surname><given-names>R.F.</given-names></name>
</person-group><article-title>Development and evaluation of a real-time PCR assay for detection of Pneumocystis jirovecii DNA in bronchoalveolar lavage fluid of HIV-infected patients</article-title><source>Thorax</source><year>2007</year><volume>63</volume><fpage>154</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1136/thx.2007.081687</pub-id><pub-id pub-id-type="pmid">17693588</pub-id>
</element-citation></ref><ref id="B24-idr-17-00047"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Larsen</surname><given-names>H.H.</given-names></name>
<name><surname>Huang</surname><given-names>L.</given-names></name>
<name><surname>Kovacs</surname><given-names>J.A.</given-names></name>
<name><surname>Crothers</surname><given-names>K.</given-names></name>
<name><surname>Silcott</surname><given-names>V.A.</given-names></name>
<name><surname>Morris</surname><given-names>A.</given-names></name>
<name><surname>Turner</surname><given-names>J.R.</given-names></name>
<name><surname>Beard</surname><given-names>C.B.</given-names></name>
<name><surname>Masur</surname><given-names>H.</given-names></name>
<name><surname>Fisher</surname><given-names>S.H.</given-names></name>
</person-group><article-title>A Prospective, Blinded Study of Quantitative Touch-Down Polymerase Chain Reaction Using Oral-Wash Samples for Diagnosis of Pneumocystis Pneumonia in HIV-Infected Patients</article-title><source>J. Infect. Dis.</source><year>2004</year><volume>189</volume><fpage>1679</fpage><lpage>1683</lpage><pub-id pub-id-type="doi">10.1086/383322</pub-id><pub-id pub-id-type="pmid">15116305</pub-id>
</element-citation></ref><ref id="B25-idr-17-00047"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brown</surname><given-names>L.</given-names></name>
<name><surname>Rautemaa-Richardson</surname><given-names>R.</given-names></name>
<name><surname>Mengoli</surname><given-names>C.</given-names></name>
<name><surname>Alanio</surname><given-names>A.</given-names></name>
<name><surname>Barnes</surname><given-names>R.A.</given-names></name>
<name><surname>Bretagne</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>S.C.</given-names></name>
<name><surname>Cordonnier</surname><given-names>C.</given-names></name>
<name><surname>Donnelly</surname><given-names>J.P.</given-names></name>
<name><surname>Heinz</surname><given-names>W.J.</given-names></name>
<etal/>
</person-group><article-title>Polymerase Chain Reaction on Respiratory Tract Specimens of Immunocompromised Patients to Diagnose Pneumocystis Pneumonia: A Systematic Review and Meta-analysis</article-title><source>Clin. Infect. Dis.</source><year>2024</year><volume>79</volume><fpage>161</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1093/cid/ciae239</pub-id><pub-id pub-id-type="pmid">38860786</pub-id>
</element-citation></ref><ref id="B26-idr-17-00047"><label>26.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Vohra</surname><given-names>S.</given-names></name>
<name><surname>Dhaliwal</surname><given-names>H.S.</given-names></name>
</person-group><article-title>Miliary Tuberculosis</article-title><source>StatPearls</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2024</year><comment>Available online: <ext-link xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK562300/" ext-link-type="uri">http://www.ncbi.nlm.nih.gov/books/NBK562300/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-15">(accessed on 15 September 2024)</date-in-citation></element-citation></ref><ref id="B27-idr-17-00047"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tabaja</surname><given-names>H.</given-names></name>
<name><surname>Kanj</surname><given-names>A.</given-names></name>
<name><surname>El Zein</surname><given-names>S.</given-names></name>
<name><surname>Comba</surname><given-names>I.Y.</given-names></name>
<name><surname>Chehab</surname><given-names>O.</given-names></name>
<name><surname>Mahmood</surname><given-names>M.</given-names></name>
</person-group><article-title>A Review of Hemophagocytic Lymphohistiocytosis in Patients with HIV</article-title><source>Open Forum Infect. Dis.</source><year>2022</year><volume>9</volume><fpage>ofac071</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofac071</pub-id><pub-id pub-id-type="pmid">35308483</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="idr-17-00047-f001"><label>Figure 1</label><caption><p>A computed tomography of the chest showing multiple ground glass opacities randomly distributed in both lung fields.</p></caption><graphic xlink:href="idr-17-00047-g001" position="float"/></fig><fig position="float" id="idr-17-00047-f002"><label>Figure 2</label><caption><p>Bronchoalveolar lavage with, as follows: (<bold>A</bold>) Hematoxylin-eosin stain revealing foamy and cottony amorphic exudates; (<bold>B</bold>) PAS (Periodic Acid Schiff) stain highlights round structures with a small central condensation suggestive of <italic toggle="yes">P. jirovecii</italic> cysts; (<bold>C</bold>,<bold>D</bold>) GMS (Grocott&#x02013;G&#x000f6;m&#x000f6;ri&#x02019;s methenamine silver) stain with magnification revealing dark brown round structures with a &#x0201c;folded spheres&#x0201d; or &#x0201c;flattened beach balls&#x0201d; appearance suggestive of <italic toggle="yes">P. jirovecii</italic> cysts.</p></caption><graphic xlink:href="idr-17-00047-g002" position="float"/></fig><fig position="float" id="idr-17-00047-f003"><label>Figure 3</label><caption><p>Bone marrow biopsy with, as follows: (<bold>A</bold>,<bold>B</bold>) Hematoxylin-eosin stain revealing foamy amorphic exudate; and (<bold>C</bold>,<bold>D</bold>) GMS (Grocott&#x02013;G&#x000f6;m&#x000f6;ri&#x02019;s methenamine silver) stain and magnification revealing dark, round small structures with no budding within myeloid and erythroid cells suggestive of <italic toggle="yes">P. jirovecii</italic> yeasts.</p></caption><graphic xlink:href="idr-17-00047-g003" position="float"/></fig><table-wrap position="float" id="idr-17-00047-t001"><object-id pub-id-type="pii">idr-17-00047-t001_Table 1</object-id><label>Table 1</label><caption><p>Laboratory findings.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Laboratory</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference Values</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Admission</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Readmission<break/>(5 Days After Discharge)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Second Discharge (38 Days After Readmission)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">White blood cell count (&#x000d7;10<sup>3</sup>/&#x003bc;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.8&#x02013;10.00</td><td align="center" valign="middle" rowspan="1" colspan="1">5.1</td><td align="center" valign="middle" rowspan="1" colspan="1">11.65</td><td align="center" valign="middle" rowspan="1" colspan="1">7.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Neutrophils (&#x000d7;10<sup>3</sup>/&#x003bc;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.40&#x02013;6.50</td><td align="center" valign="middle" rowspan="1" colspan="1">3.03</td><td align="center" valign="middle" rowspan="1" colspan="1">9.84</td><td align="center" valign="middle" rowspan="1" colspan="1">5.4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lymphocytes (&#x000d7;10<sup>3</sup>/&#x003bc;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.80&#x02013;4.00</td><td align="center" valign="middle" rowspan="1" colspan="1">1.54</td><td align="center" valign="middle" rowspan="1" colspan="1">1.13</td><td align="center" valign="middle" rowspan="1" colspan="1">1.37</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Monocytes (&#x000d7;10<sup>3</sup>/&#x003bc;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00&#x02013;0.70</td><td align="center" valign="middle" rowspan="1" colspan="1">0.36</td><td align="center" valign="middle" rowspan="1" colspan="1">0.66</td><td align="center" valign="middle" rowspan="1" colspan="1">0.47</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Eosinophils (&#x000d7;10<sup>3</sup>/&#x003bc;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00&#x02013;2.00</td><td align="center" valign="middle" rowspan="1" colspan="1">0.15</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.03</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hematocrit (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">45.0&#x02013;54.0</td><td align="center" valign="middle" rowspan="1" colspan="1">48.5</td><td align="center" valign="middle" rowspan="1" colspan="1">50.2</td><td align="center" valign="middle" rowspan="1" colspan="1">33.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hemoglobin (g/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">14.0&#x02013;18.0</td><td align="center" valign="middle" rowspan="1" colspan="1">16.5</td><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">11.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Platelets (&#x000d7;10<sup>3</sup>/&#x003bc;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">150&#x02013;450</td><td align="center" valign="middle" rowspan="1" colspan="1">141</td><td align="center" valign="middle" rowspan="1" colspan="1">70</td><td align="center" valign="middle" rowspan="1" colspan="1">303</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">C-reactive Protein (mg/L)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00&#x02013;10.00</td><td align="center" valign="middle" rowspan="1" colspan="1">22.4</td><td align="center" valign="middle" rowspan="1" colspan="1">76.06</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lactate Dehydrogenase (U/L)</td><td align="center" valign="middle" rowspan="1" colspan="1">98.00&#x02013;192.00</td><td align="center" valign="middle" rowspan="1" colspan="1">331</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Total Bilirubin (mg/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.30&#x02013;1.20</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">15.3</td><td align="center" valign="middle" rowspan="1" colspan="1">2.54</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Direct bilirubin (mg/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.10&#x02013;0.50</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">10.2</td><td align="center" valign="middle" rowspan="1" colspan="1">1.17</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Alanine <break/>aminotransferase (U/L)</td><td align="center" valign="middle" rowspan="1" colspan="1">17.00&#x02013;63.00</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">75.5</td><td align="center" valign="middle" rowspan="1" colspan="1">31.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Aspartate <break/>aminotransferase (U/L)</td><td align="center" valign="middle" rowspan="1" colspan="1">15.00&#x02013;41.00</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">104.12</td><td align="center" valign="middle" rowspan="1" colspan="1">44.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Blood urea nitrogen (mg/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.00&#x02013;20.00</td><td align="center" valign="middle" rowspan="1" colspan="1">8.74</td><td align="center" valign="middle" rowspan="1" colspan="1">17.4</td><td align="center" valign="middle" rowspan="1" colspan="1">25.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Creatinine (mg/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.61&#x02013;1.24</td><td align="center" valign="middle" rowspan="1" colspan="1">0.39</td><td align="center" valign="middle" rowspan="1" colspan="1">0.92</td><td align="center" valign="middle" rowspan="1" colspan="1">0.85</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">pH</td><td align="center" valign="middle" rowspan="1" colspan="1">7.350&#x02013;7.450</td><td align="center" valign="middle" rowspan="1" colspan="1">7.45</td><td align="center" valign="middle" rowspan="1" colspan="1">7.51</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SaO<sub>2</sub> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">80.0&#x02013;100.0</td><td align="center" valign="middle" rowspan="1" colspan="1">92.6</td><td align="center" valign="middle" rowspan="1" colspan="1">93</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PaO<sub>2</sub> (mmHg)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">75.2</td><td align="center" valign="middle" rowspan="1" colspan="1">66</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PCO<sub>2</sub> (mmHg)</td><td align="center" valign="middle" rowspan="1" colspan="1">26.0&#x02013;50.0</td><td align="center" valign="middle" rowspan="1" colspan="1">31</td><td align="center" valign="middle" rowspan="1" colspan="1">26</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HCO<sub>3</sub> (mmol/L)</td><td align="center" valign="middle" rowspan="1" colspan="1">18.0&#x02013;23.0</td><td align="center" valign="middle" rowspan="1" colspan="1">21.4</td><td align="center" valign="middle" rowspan="1" colspan="1">21</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">FiO<sub>2</sub> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">40</td><td align="center" valign="middle" rowspan="1" colspan="1">21</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PaO<sub>2</sub>/FiO<sub>2</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">188</td><td align="center" valign="middle" rowspan="1" colspan="1">314</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alveolar&#x02013;arterial gradient</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="idr-17-00047-t002"><object-id pub-id-type="pii">idr-17-00047-t002_Table 2</object-id><label>Table 2</label><caption><p>A summary of infectious data.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Laboratory</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Specimen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Results</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Aerobic and anaerobic cultures</td><td align="center" valign="middle" rowspan="1" colspan="1">Blood</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Treponema pallidum</italic> (VDRL)</td><td align="center" valign="middle" rowspan="1" colspan="1">Blood</td><td align="center" valign="middle" rowspan="1" colspan="1">Positive (1:4 dilutions)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HIV antibodies</td><td align="center" valign="middle" rowspan="1" colspan="1">Blood</td><td align="center" valign="middle" rowspan="1" colspan="1">Positive</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Human immunodeficiency<break/>virus viral load (copies/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">Blood</td><td align="center" valign="middle" rowspan="1" colspan="1">Positive (2,095,776)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lymphocytes CD4 (cells/mm<sup>3</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">Blood</td><td align="center" valign="middle" rowspan="1" colspan="1">33</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lymphocytes CD45 (cells/mm<sup>3</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">Blood</td><td align="center" valign="middle" rowspan="1" colspan="1">524</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lymphocytes CD3 (cells/mm<sup>3</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">Blood</td><td align="center" valign="middle" rowspan="1" colspan="1">368</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lymphocytes CD8 (cells/mm<sup>3</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">Blood</td><td align="center" valign="middle" rowspan="1" colspan="1">305</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hepatitis A antibodies</td><td align="center" valign="middle" rowspan="1" colspan="1">Blood</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hepatitis B antigen</td><td align="center" valign="middle" rowspan="1" colspan="1">Blood</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hepatitis C antibodies</td><td align="center" valign="middle" rowspan="1" colspan="1">Blood</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cytomegalovirus IgG antibodies</td><td align="center" valign="middle" rowspan="1" colspan="1">Blood</td><td align="center" valign="middle" rowspan="1" colspan="1">Positive (30.3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cytomegalovirus IgM antibodies</td><td align="center" valign="middle" rowspan="1" colspan="1">Blood</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Typhoid O Antibodies<break/>(latex agglutination)</td><td align="center" valign="middle" rowspan="1" colspan="1">Blood</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Typhoid H Antibodies<break/>(latex agglutination)</td><td align="center" valign="middle" rowspan="1" colspan="1">Blood</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Brucella abortus</italic> Antibodies<break/>(latex agglutination)</td><td align="center" valign="middle" rowspan="1" colspan="1">Blood</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Aspergillus</italic> Galactomannan Antigen (lateral flow assay)</td><td align="center" valign="middle" rowspan="1" colspan="1">Blood</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Mycobacterium tuberculosis</italic> PCR<break/>(GeneXpert Ultra)</td><td align="center" valign="middle" rowspan="1" colspan="1">Sputum</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Leptospira</italic> IgM Antibodies</td><td align="center" valign="middle" rowspan="1" colspan="1">Blood</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Histoplasma</italic> Antigen</td><td align="center" valign="middle" rowspan="1" colspan="1">Urine</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Cryptococcus</italic> Antigen<break/>(latex agglutination)</td><td align="center" valign="middle" rowspan="1" colspan="1">Blood</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Epstein Barr IgG Antibodies</td><td align="center" valign="middle" rowspan="1" colspan="1">Blood</td><td align="center" valign="middle" rowspan="1" colspan="1">Positive</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Epstein Barr IgM Antibodies</td><td align="center" valign="middle" rowspan="1" colspan="1">Blood</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ziehl-Neelsen</td><td align="center" valign="middle" rowspan="1" colspan="1">Bronchoalveolar lavage</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Mycobacterium tuberculosis</italic> PCR<break/>(GeneXpert Ultra)</td><td align="center" valign="middle" rowspan="1" colspan="1">Bronchoalveolar lavage</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Direct Fungal Microscopy</td><td align="center" valign="middle" rowspan="1" colspan="1">Bronchoalveolar lavage</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Aspergillus</italic> Galactomannan Antigen</td><td align="center" valign="middle" rowspan="1" colspan="1">Bronchoalveolar lavage</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mycobacteria Growth Indicator Tube</td><td align="center" valign="middle" rowspan="1" colspan="1">Bronchoalveolar lavage</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fungal Culture</td><td align="center" valign="middle" rowspan="1" colspan="1">Bronchoalveolar lavage</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Common Microorganisms Culture</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bronchoalveolar lavage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negative</td></tr></tbody></table></table-wrap><table-wrap position="float" id="idr-17-00047-t003"><object-id pub-id-type="pii">idr-17-00047-t003_Table 3</object-id><label>Table 3</label><caption><p>Cases of <italic toggle="yes">P. jirovecii</italic> bone marrow infection reported worldwide.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Author and Year</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sex and Age</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical <break/>Manifestations</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Hematological<break/>Manifestations</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Medical Records</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Extramedullary <break/>Infection</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Concomitant <break/>Conditions</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Diagnosis</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treatment</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Outcomes</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" colspan="1">Rossi, J.F., et al. (1985) [<xref rid="B7-idr-17-00047" ref-type="bibr">7</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">F/75</td><td align="center" valign="middle" rowspan="1" colspan="1">Cervical mass, signs and symptoms of hypercalcemia</td><td align="center" valign="middle" rowspan="1" colspan="1">Pancytopenia</td><td align="center" valign="middle" rowspan="1" colspan="1">Lymphoplasmacytic lymphoma in chemotherapy </td><td align="center" valign="middle" rowspan="1" colspan="1">PCP (postmortem findings)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Candida albicans</italic> septicemia</td><td align="center" valign="middle" rowspan="1" colspan="1">Bone marrow biopsy (G with amorphous eosinophilic material and some organisms with a central red nucleus and pale blue cytoplasm were seen, GMS with PJ cystic walls)</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">Death</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">M/36</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Respiratory failure</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Anemia, severe thrombocytopenia</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Hodgkin&#x02019;s disease in chemotherapy and radiotherapy, Hip osteonecrosis, Pulmonary fibrosis</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">PCP (first)</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Bacteroides melaninogenica</italic> infection in hip</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Bone marrow biopsy (G with amorphous eosinophilic material and some organisms with a central red nucleus and pale blue cytoplasm were seen, GMS with PJ cystic walls)</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Death</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Heyman, M.R., et al. (1987) [<xref rid="B5-idr-17-00047" ref-type="bibr">5</xref>]</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">M/34</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Weight loss, dyspnea, arthralgias, myalgias, malaise, anorexia, hair loss, fever (38.2 &#x000b0;C), night sweats and decreasing visual acuity</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pancytopenia</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">AIDS (CD4 count and viral load unknown), diabetes</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PCP (first)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CMV retinitis, oral candidiasis, <italic toggle="yes">Mycobacterium avium intracellulare</italic> infection in bone marrow and lungs; CMV infection in lungs and liver (postmortem findings), <italic toggle="yes">Mycobacterium</italic> infection in liver, colon and lymph nodes (postmortem findings)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Bone marrow biopsy (GMS with numerous extracellular PJ organisms)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cotrimoxazole</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Death</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unger, P.D., et al. (1988) [<xref rid="B8-idr-17-00047" ref-type="bibr">8</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M/40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Decreasing visual acuity, progressive confusion and withdrawal, decreased urinary output, and severe dyspnea</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AIDS (CD4 count and viral load unknown), KS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PCP (first), PJ infection of spleen, lymph nodes, adrenal gland, Virchow&#x02013;Robin spaces (postmortem findings)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Staphylococcus aureus</italic> sepsis, KS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-mortem histologic examination of bone marrow (GMS with PJ cysts in characteristic ovoid, crescentic, and helmet-shaped configurations, MC stain was negative)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Death</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lubat, E., et al. (1990) [<xref rid="B9-idr-17-00047" ref-type="bibr">9</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bone marrow biopsy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amin, M.B., et al. (1990) [<xref rid="B10-idr-17-00047" ref-type="bibr">10</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M/29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dyspnea, weakness, progressive cough, fever, cervical adenopathy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pancytopenia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AIDS (CD4 count and viral load unknown)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PCP (first), PJ infection of lymph nodes, liver, spleen and kidneys (postmortem findings)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-mortem histologic examination of bone marrow (GMS with PJ cysts and amorphous exudates)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dapsone, azidothymidine, aerosolized pentamidine, and aspirin (cotrimoxazole allergy)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Death</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Telzak, E.E., et al. (1990) [<xref rid="B3-idr-17-00047" ref-type="bibr">3</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M/33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fever, chest pain, lethargy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pancytopenia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AIDS (CD4 count and viral load unknown), KS, <italic toggle="yes">Candida</italic> esophagitis, Herpes zoster of the neck and jaw, CMV retinitis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PCP (first), PJ infection in liver, spleen, adrenals, kidneys and pituitary (postmortem findings)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KS involving the skin, trachea, lungs, duodenum, lymph nodes, and bone marrow; <italic toggle="yes">Mycobacterium avium intracellulare</italic> infection in lungs, lymph nodes and spleen; CMV infection in adrenal medulla (postmortem findings)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-mortem histologic examination of bone marrow (H-E with fluffy eosinophilic material and GMS with complete replacement of hematopoietic elements by dark round structures suggestive of PJ cysts)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broad-spectrum antibiotics</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Death</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rossi, J.F., et al. (1990) [<xref rid="B6-idr-17-00047" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M/74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Respiratory failure</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alcoholic cirrhosis, in situ gastric neoplasm, AIDS (T CD4/CD8 0.7 ratio)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PCP (first)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bone marrow biopsy (G with foamy eosinophilic material, GMS with PJ cystic walls)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Death</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Momose, H., et al. (1991) [<xref rid="B11-idr-17-00047" ref-type="bibr">11</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M/35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fatigue and dyspnea</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AIDS (CD4 count and viral load unknown), CMV retinitis, KS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PCP (first)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CMV retinitis, KS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bone marrow biopsy (H-E stain with a focus of foamy eosinophilic exudate with otherwise unremarkable hematopoietic elements; GMS showed PJ cysts; Immunoperoxidase stain positive for PJ on the eosinophilic material)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous<break/>pentamidine switched to oral cotrimoxazole</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Death</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Grier, D.D., et al. (2009) [<xref rid="B4-idr-17-00047" ref-type="bibr">4</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F/34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shortness of breath, abdominal distention, and lower extremity edema</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pancytopenia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cutaneous T cell lymphoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PJ infection of peritoneum and spleen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Disseminated <italic toggle="yes">Candida</italic> and CMV infections</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bone marrow biopsy (H-E stain with focal aggregates of foamy eosinophilic material; GMS stain demonstrated numerous cup-shaped organisms consistent with PJ)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Death</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lerdlamyong, K., et al. (2017) [<xref rid="B12-idr-17-00047" ref-type="bibr">12</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M/45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fever, weight loss</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anemia, leukopenia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AIDS (CD4 count 0.01 &#x000d7; 10<sup>9</sup>/L, viral load undetectable)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PCP (first)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cryptococcal meningitis, CMV retinitis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bone marrow biopsy (H-E stain, multiple small clusters of histiocytes containing several small yeast cells; GMS, numerous intracellular cup-shaped yeast cells without mucinous capsule, with lack of budding; MC staining was negative)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clindamycin and primaquine for 3 weeks, then dapsone for secondary prophylaxis (cotrimoxazole allergy)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Symptoms and hematologic compromise improved on treatment.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">this work</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M/34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fatigue, diaphoresis, weight loss, dry cough, diarrhea, dyspnea</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thrombocytopenia with progression to pancytopenia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AIDS (CD4 Count: 33 cells/mL<sup>3</sup>. Viral load: 2,095,776 copies/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PCP (first)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Syphilis, Oral candidiasis, KS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bone marrow biopsy (H-E stain with foamy amorphic exudates; GMS with dark round small structures with no budding within myeloid and erythroid cells suggestive of PJ yeasts)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cotrimoxazole for 21 days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical improvement, died two months later</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: CMV, Cytomegalovirus; G, Giemsa; GMS, G&#x000f6;m&#x000f6;ri&#x02019;s methenamine silver; H-E, Hematoxylin and eosin; KS, Kaposi&#x02019;s sarcoma; MC, Mucicarmine; ND, Not Described; PCP, <italic toggle="yes">Pneumocystis jirovecii</italic> pneumonia; PJ, <italic toggle="yes">Pneumocystis jirovecii</italic>.</p></fn></table-wrap-foot></table-wrap></floats-group></article>